National Research (NRC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for May 7, 2025, to be held virtually, with record date set as March 20, 2025.
Key proposals include election of two directors, ratification of KPMG LLP as auditor, advisory vote on executive compensation, and approval of the 2025 Omnibus Incentive Plan.
Shareholders can vote online, by phone, or by mail until May 6, 2025.
Voting matters and shareholder proposals
Election of two directors for terms expiring in 2028.
Ratification of KPMG LLP as independent registered public accounting firm for 2025.
Advisory vote on executive compensation (say-on-pay).
Approval of the 2025 Omnibus Incentive Plan to replace prior equity plans.
Shareholder proposals for 2026 must be received by December 11, 2025, for proxy inclusion.
Board of directors and corporate governance
Board consists of six directors, with five deemed independent under NASDAQ standards.
New CEO, Trent Green, appointed effective June 1, 2025; outgoing CEO transitions to Chairman.
Board committees: Audit, Compensation and Talent, Nominating, and Strategic Planning.
Lead director role maintained for independent oversight.
Majority vote policy for director elections and proxy access for shareholders with 3%+ ownership for three years.
Latest events from National Research
- Q4 2025 revenue rose 2%, TRCV up 8% YoY, and a $0.16 dividend was declared.NRC
Q4 20253 Feb 2026 - Huey AI enhances healthcare experience management with tailored, ethical, and privacy-focused solutions.NRC
Status Update3 Feb 2026 - Timely, representative feedback and focus on key drivers accelerate patient experience improvement.NRC
Status update2 Feb 2026 - Significant CAHPS and HCAHPS survey changes and reporting updates are set for 2025–2030.NRC
Status Update22 Jan 2026 - AI and digital tools can transform healthcare if implemented transparently and with human well-being at the core.NRC
Status Update13 Jan 2026 - TRCV grew 2% as Q2 2025 revenue fell and executive compensation drove a net loss.NRC
Q2 202516 Nov 2025 - Q3 2025 saw higher adjusted EBITDA, record retention, and a 33% dividend increase.NRC
Q3 20257 Nov 2025 - Revenue and net income declined, but cash flow and shareholder returns increased.NRC
Q3 202413 Jun 2025 - Revenue and net income fell, but acquisitions and product innovation signal future growth.NRC
Q2 202413 Jun 2025